Oscar Tahuahua: Promising Phase II Results for Pembrolizumab and MVAC in Nonurothelial MIBC
Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X about a paper by Ruben Raychaudhuri et al. published in European Urology:
“Neoadjuvant pembrolizumab (×3) plus accelerated MVAC (×4, q2w) in nonurothelial MIBC
Ph2, single-arm: pCR 53%, downstaging 59%, 2-yr EFS 64%, OS 79%. Grade 3 AEs 47%, no Tx-related deaths. Mostly cT2 (59%) and cN0 (94%), rare and aggressive subtypes.”
Title: Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial
Authors: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, Kelsey K. Baker, Kevin Ng, Xueyan Chen, Jenny Mao, Brianna Woo, Aaron Lin, Andrii Hannochka, Nathan Conrad, Martha Kahugu, Patrick Panlasigui, Michael C. Haffner, Andrew C. Hsieh, Hung-Ming Lam, Funda Vakar-Lopez, Todd Yezefski, Michael T. Schweizer, Robert B. Montgomery, Evan Y. Yu, Atreya Dash, Sarah P. Psutka, Daniel W. Lin, George R. Schade, John L. Gore, Jonathan L. Wright, Petros Grivas
You can read the Full Article on European Urology.
More posts featuring Oscar Tahuahua.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023